154 related articles for article (PubMed ID: 12412483)
1. Generation and characterization of bispecific tandem diabodies for tumor therapy.
Kipriyanov SM
Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
[No Abstract] [Full Text] [Related]
2. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
3. Generation of bispecific and tandem diabodies.
Kipriyanov SM
Methods Mol Biol; 2002; 178():317-31. PubMed ID: 11968501
[No Abstract] [Full Text] [Related]
4. Bispecific diabodies for cancer therapy.
Arndt M; Krauss J
Methods Mol Biol; 2003; 207():305-21. PubMed ID: 12412482
[No Abstract] [Full Text] [Related]
5. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
6. Generation of bispecific and tandem diabodies.
Kipriyanov SM
Methods Mol Biol; 2009; 562():177-93. PubMed ID: 19554296
[TBL] [Abstract][Full Text] [Related]
7. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
Kipriyanov SM; Moldenhauer G; Strauss G; Little M
Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
[TBL] [Abstract][Full Text] [Related]
8. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
9. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
10. Toward the production of bispecific antibody fragments for clinical applications.
Carter P; Ridgway J; Zhu Z
J Hematother; 1995 Oct; 4(5):463-70. PubMed ID: 8581386
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M
J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
13. [Biologic activity of bispecific single chain antibody against human gamma-seminoprotein and CD3 molecule].
Wang D; Wang H; Wu GJ; Wu WZ; Yang SL; Lin WH; Tan JM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):500-3. PubMed ID: 16806016
[TBL] [Abstract][Full Text] [Related]
14. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy.
Niv R; Segal D; Reiter Y
Methods Mol Biol; 2003; 207():255-68. PubMed ID: 12412479
[No Abstract] [Full Text] [Related]
15. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.
McAleese F; Eser M
Future Oncol; 2012 Jun; 8(6):687-95. PubMed ID: 22764766
[TBL] [Abstract][Full Text] [Related]
16. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
18. Production of bispecific antibodies: diabodies and tandem scFv.
Hornig N; Färber-Schwarz A
Methods Mol Biol; 2012; 907():713-27. PubMed ID: 22907382
[TBL] [Abstract][Full Text] [Related]
19. [Construction and expression of single chain variable fragments (ScFv) against human CD19 antigen].
Chen S; Rao Q; Wang JX; Wang M
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):686-91. PubMed ID: 16285505
[TBL] [Abstract][Full Text] [Related]
20. "Diabodies": small bivalent and bispecific antibody fragments.
Holliger P; Prospero T; Winter G
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6444-8. PubMed ID: 8341653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
